OS from the time of first relapse/progression in patients with multiple myeloma treated with auto/RICallo or auto alone. The survival from first relapse/progression was significantly longer in the auto/RICallo arm than in the auto arm: 50% with auto/RICallo vs 27% with auto at 60 months from progression (P = .003). All patients who reached first relapse/progression included. Gray = auto/RICallo; black = auto.